Sentences with phrase «of olaparib»

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 mg twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).

«We are really excited to now be moving forward with the next phase of our trial, which will be a key step in the evaluation of olaparib in advanced prostate cancer.»

In this study, the researchers tested the effects of Olaparib on the tumors formed by human breast cancer cells injected into mice.

Not exact matches

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

«This suggests that PGAM1 inhibitors can sensitize cancers to PARP inhibitors such as Olaparib, thereby expanding the benefits of PARP inhibitors to BRCA1 / 2 - proficient cancers, particularly triple - negative breast cancers that currently lack effective therapies,» says author Min Huang.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

Pre-clinical studies suggest these agents add to and enhance the activity of each other, and a phase 1 study showed that the combination of cediranib and olaparib was well - tolerated with minimal side - effects.

PARP (Poly ADP - Ribose Polymerase) inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.

«The results from this innovative clinical trial are very promising and highlight the potential for olaparib — and other PARP inhibitors — to treat a wide range of cancers.

«Our trial shows that olaparib is effective in men with defects in DNA repair genes who do not necessarily have an inherited risk of cancer — and that we can pick up these defects in the clinic.

Professor Steve Jackson, Head of Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute — whose CRUK - funded research led him to establish and scientifically lead the company KuDOS, which developed olaparib — said:

Of the 16 patients with detectable DNA repair mutations, 14 responded to olaparib — accounting for the large majority of patients who benefited from the druOf the 16 patients with detectable DNA repair mutations, 14 responded to olaparib — accounting for the large majority of patients who benefited from the druof patients who benefited from the drug.

Zhang's team began by combining the PARP inhibitor olaparib with 20 different helper compounds, and eventually discovered a family of drugs called BET inhibitors that work with olaparib to attack cancer cells.

As of March 2014, median progression - free survival was 9.2 months for olaparib and 16.7 months for the combination therapy, which is a significant advantage.

The results will lead on to the start of TOPARP - B, a second part of the trial in which only men with detectable DNA repair mutations will receive olaparib.

In the trial, researchers monitored the response of 49 men with treatment - resistant, advanced prostate cancer to olaparib.

If the results of TOPARP - A are replicated in TOPARP - B, olaparib could become a treatment option in advanced prostate cancer.

«This is the first study to test the promise of a new kind of drug, olaparib, for life - threatening prostate cancer no longer responding to best available treatment.

The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone.

Men with prostate cancer benefit from treatment with the pioneering drug olaparib — the first cancer drug to target inherited mutations — according to the results of a major trial.

«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Boston.

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

Three PARPis — olaparib, niraparib, and rucaparib — were recently approved by the FDA for the treatment of breast and ovarian cancers.

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (OLAParib COmbinations)

Samples that were resistant and treated with the PARP inhibitor olaparib showed a higher percentage of RAD51 - positive cells than those that were PARP inhibition — sensitive (36 % vs 5 %; P =.0017).

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not received Prior VEGF Therapy

Tumours shrank in about 60 % of women who received the targeted drug, called olaparib (Lynparza), compared with 29 % of those who received chemotherapy.

A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.

An international research team, led by University College London's Professor Jonathan Ledermann, carried out a trial to see whether olaparib could have a role to play in preventing ovarian cancer from coming back in this group of patients.

The researchers found that women who took olaparib had a median of 8.4 months before their cancer came back, compared to 4.8 months for those on the placebo.

Cancer Research UK, who did not fund the trial but have played an important role in the development of PARP inhibitors like olaparib, said the results highlighted their potential.

Olaparib was also detected in 27 of 28 tumour margin specimens from 10 patients (mean concentration 500nM).

Treating women with olaparib, a new type of experimental drug called a PARP inhibitor, after their initial cancer treatment, may help prevent their ovarian cancer from coming back, according to a phase - II clinical trial led by UK scientists.

However, the mechanism of resistance in prostate cancer, and to PARPi other than olaparib, is unknown.

Professor Susan Short, member of NCRI's Radiotherapy Research Working Group, said: «We're just beginning to realise the full potential of PARP inhibitors to tackle many different types of cancer, so it's exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.

** Olaparib was detected in 73 of 74 tumour core specimens from 27 patients (mean concentration: 588nM).